Latest news with #lungcancer
BBC News
15 hours ago
- General
- BBC News
Sketty broken lift means man, 80 with cancer must climb stairs
A resident with lung cancer has been forced to climb to the fourth floor of his block of flats because of a broken lift. Brian Dabbs, 80, said the lift in the Runnymede Court block in Sketty, Swansea, broke down on suffers from mesothelioma, and says he is worried it will be five days until it is Housing apologised and said it is trying to fix the lift. "People have been stuck in there for maybe three times in the last three months, and it happened again on Sunday," Mr Dabbs said. "I've spoken to the one lady that was stuck in the lift and there were two people in there altogether - a lady, a man and a dog. "I'd gone out for food on Sunday and when I came back I was told I had to walk up the stairs."I live on the top floor, and I'm suffering from mesothelioma and I've got a shortness of breath and I need that lift to get out." He added: "So today (Tuesday), I've had to come out for a prescription and I've got to walk up the stairs to get up there. I rest on every floor."It's just so inconvenient. It's unbelievable. My friend phoned the lift company and said they couldn't fix it till Friday. So we've got another few days before it gets fixed." Beacon Housing told BBC Wales it was made aware the lift had developed a fault on Sunday.A spokesman said: "Lift contractors attended within the hour to assess the issue but due to the nature of the fault, parts are required to restore its operation. "These were ordered and repairs will be completed promptly once received. However, the indicative timescale provided to homeowners for repair reflects the time that parts will take to be delivered. "We apologise for the inconvenience and are making every effort to reinstate the lift promptly."We have had no contact from homeowners at Runnymede beyond the initial reporting on Sunday and are therefore unaware of anyone experiencing individual difficulties. If they contact us, we can put them in touch with relevant support based on their individual circumstances."
Yahoo
19 hours ago
- Business
- Yahoo
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, July 22, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. "As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives," said Maria Zannes, President and CEO of bioAffinity Technologies. Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking. "We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science," Ms. Zannes said. "Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics." The Canadian patent (Patent No. 3,136,245) – titled "System and Method for Determining Lung Health" – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. About CyPath® Lung CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. View source version on Contacts bioAffinity Technologies Julie Anne OvertonDirector of Communicationsjao@ Investor Relations Dave GentryRedChip Companies Inc.1-800-RED-CHIP (733-2447) or 407-491-4498BIAF@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
a day ago
- Health
- New York Times
Many Lung Cancers Are Now in Nonsmokers. Scientists Want to Know Why.
Annie Chen first noticed she was unusually short of breath in 2017, while running to catch the bus home to New Jersey from her job in Manhattan. She told her primary care doctor, thinking of her father, who died of lung cancer at 71. But her doctor told her not to worry — her father was a heavy smoker, and Ms. Chen had never smoked. She continued to have difficulty breathing, but it wasn't until two years later that a doctor ordered an X-ray, and Ms. Chen was diagnosed with Stage 4 lung cancer. 'My whole world crashed,' she said. She was just 48, with an 11-year-old daughter, a husband who also had health issues and a mortgage to pay off. 'My family needs me,' she recalled thinking. Ms. Chen's case represents a confounding reality for doctors who study and treat lung cancer, the deadliest cancer in the United States. The disease's incidence and death rates have dropped over the last few decades, thanks largely to a decline in cigarette use, but lung cancers unrelated to smoking have persisted. The thinking used to be that smoking was 'almost the only cause of lung cancer,' said Dr. Maria Teresa Landi, a senior investigator at the National Cancer Institute, which is part of the National Institutes of Health. But worldwide, roughly 10 to 25 percent of lung cancers now occur in people who have never smoked. Among certain groups of Asian and Asian American women, that share is estimated to be 50 percent or more. These cancers are increasingly drawing the attention of researchers like Dr. Landi, who are studying the role that environmental exposures, genetic mutations or other risk factors might play. They have already found some early hints, including a clear link to air pollution. Physicians are also testing new approaches to better detect lung cancer in nonsmokers, and trying to understand why it is more prevalent in people of Asian ancestry and women and why it is being seen among younger people. Want all of The Times? Subscribe.
Daily Mail
a day ago
- Entertainment
- Daily Mail
Legendary Australian singer and Blue Heelers star Bobby Bright dies at 80 after devastating diagnosis
Legendary Australian singer-turned-actor Bobby Bright has died in Melbourne aged 80, three years after being diagnosed with lung cancer. The English-born singer moved to Australia at the age of nine and had an incredible career in both music and film, which lasted for over five decades. He was renowned for his long-time partnership with fellow singer Laurie Allen, after they joined forces in 1964 to form the celebrated duo Bobby & Laurie. They quickly became fixtures on Australian television, including regular appearances on the variety program The Go!! Show. Their debut record, I Belong with You, released under Melbourne 's Go!! Records, marked the beginning of their musical journey together. From A-list scandals and red carpet mishaps to exclusive pictures and viral moments, subscribe to the DailyMail's new showbiz newsletter to stay in the loop. The duo's collaboration with The Rondells, featuring Wayne Duncan on bass and Gary Young on drums (later of Daddy Cool fame), produced hits that catapulted them to pop stardom. Their cover of Roger Miller's 'Hitch Hiker' soared to number one in Australia in 1966, cementing their place in music history. They also co-hosted a popular ABC musical variety show in 1966 called Dig We Must. In addition to his musical achievements, Bobby Bright pursued occasional acting roles. He notably appeared in the legendary Channel Seven police drama Homicide and took on the role of The Doctor in the Australian stage production of 'Tommy' in 1973. Bobby went on to become a fixture of Australian film and television, appearing alongside Lisa McCune in Blue Heelers and late American singer Aaliyah in the Melbourne-filmed Hollywood movie Queen of the Damned. Bobby's final acting role was in a 2015 short movie called Lazy Boy, alongside Neighbours star Steven Carroll. He also ventured into radio, serving as a DJ on Melbourne's 3XY. Heartbroken fans took to social media to pay tribute to Bobby. 'Very sad news. A lovely man,' one person wrote. 'Recorded some great music,' a second added. Following a career that spanned decades, Bobby continued to perform in Melbourne. He never retired and continued to wow crowds across Australia with his incredible performances until shortly before his death. His singing partner Laurie Allen passed away in 2002, and together they leave behind a legacy of unforgettable contributions to Australian music and entertainment.
Daily Mail
a day ago
- Health
- Daily Mail
EXCLUSIVE Woman claims her life is shattered after Harvard hospital allegedly severs artery during routine surgery
A Massachusetts woman is suing Harvard University's prestigious teaching hospital claiming she had to have her lung removed following what was supposed to be a routine procedure. Elizabeth Kousoubris, a 54-year-old mother of two and Boston University adjunct professor, alleges in her lawsuit that a minimally invasive surgery at Massachusetts General Hospital (MGH) spiraled into a life-altering ordeal due to a critical surgical error. According to court filings, surgeons accidentally severed her pulmonary artery - a blood vessels that carries oxygen from the heart to lungs - cutting off blood supply to her lung and forcing its removal. Kousoubris, a lifelong athlete, told she had lived a 'pristine lifestyle,' running marathons and never smoking a cigarette. But a routine x-ray in 2021 revealed a small, slow-growing cancerous mass on her right lung, according to court documents. Doctors monitored it for more than a year before advising surgery in April 2023. Trusting the reputation of MGH, one of the nation's leading academic medical centers, Kousoubris agreed to undergo what she believed would be a straightforward operation to remove the mass. Instead, her family claims in a lawsuit that a surgical mistake triggered a cascade of life-threatening complications. The severed artery deprived her lung of blood and caused it to rapidly deteriorate. Kousoubris spent several days in critical condition before surgeons were forced to remove the entire lung, the family and court documents say. Kousoubris told 'There's a level of comfort when you go to Mass General. You know they deal with complex situations. 'You know that they have top people. And then to have this happen and to have this stone barrier erected basically to prevent culpability. How in God's name did this happen?' Now, she and her husband, Dr. Philip Kousoubris, a neuroradiologist in the Boston area, are suing MGH for medical malpractice. Independent medical experts reviewing the case concluded that Kousoubris' care 'fell below the accepted standard of care,' directly resulting in the loss of her lung, according to a letter from the physicians shared with In response to the allegations, a spokesperson for Mass General Brigham told 'While we are unable to comment on ongoing litigation, we are committed to providing safe, high quality care for our patients and always strive for the best possible outcomes and to ensure patients are aware of any potential complications prior to treatment. 'Complex surgeries such as the one described have many known risks. Our clinical teams discuss these risks with each patient prior to every surgery to ensure the patient is able to make their own informed decision.' Court documents provided to by MGH show the hospital has denied all accusations. In June 2023, Kousoubris underwent a video-assisted thoracoscopic lobectomy (VATS), a minimally invasive procedure meant to remove a lobe using small incisions, court documents show. Kousoubris said: 'Everything that could go wrong, except for the fact that I lived, did.' Doctors allegedly were able to determine within the first hour of the procedure that Kousoubris had lymphoma, court documents show. They determined this through sampling the mass and sending it to pathology. However, the family says the surgical team allegedly didn't call Dr Kousoubris to tell him they found cancer or ask what further steps to take. Instead, they removed Kousoubris' entire upper right lobe of her lung to take out the mass, which was not part of the procedure. A three-hour surgery quickly turned into seven hours, the family says. Kousoubris spent two days in the hospital without complications before doctors sent her 'home to die,' she told On her third day home from the hospital, Kousoubris says she spiked a high fever and was hit with extreme nausea. She then returned to the hospital. Detailed in the complaint, CT scans revealed the pulmonary artery had been severed and stapled to her lung, which meant there was no blood flow to the lung. Kousoubris said she laid in a hospital bed for two days in 'indescribable' pain as her right lung became necrotic and died. Her only hope of surviving was a pneumonectomy, a risky operation that involves removing an entire lung. The pneumonectomy was successful, but Kousoubris was left in the ICU with only one lung, the complaint says. Once a lifelong athlete, she would have to learn how to walk, swim and even go outside again. Dr Kousoubris told this website: 'Elizabeth was botched and she never should have been.' He compared it to losing an eye during Lasik. 'This does not happen,' he said. Dr Keith Horvath, a cardiothoracic surgeon in the Washington DC area, consulted on the case as part of the Kousoubris family's ongoing lawsuit against MGH. He was not involved in the surgery. In a letter written to Kousoubris' lawyers, reviewed by Dr Horvath wrote: 'In my professional opinion, to a reasonable degree of medical certainty, Ms. Kousoubris, age 52, suffered the loss of her right lung as a direct result of the substandard care and treatment rendered to her by thoracic surgeon.' The family said they consulted with independent doctors who claimed if a pulmonary artery is severed during surgery, it would immediately be noticeable, as the lung would change color. Dr Korvath in his letter also accused MGH of refusing to provide video of the procedure and instead allegedly sent him an 'incomplete' 32-minute audio recording that 'fails to include video of the stapling and division of critical structures which is at issue.' After a year and a half of subpoenas, MGH allegedly still has not provided video from the surgery, according to the complaint and the family. Dr Kousoubris, who spent several years practicing at Mass General before moving to another institution, said: 'There is a culture of denial and elitism and lack of culpability there that they cannot be touched. There is a culture there of coverup.' 'Nobody has the courage to stand up to the giant,' Kousoubris added. Kousoubris had a new battle to face when she came home from the hospital. Though she credits her strict diet and exercise routine for helping the process, she is far from recovered. 'Nothing could have prepared me for the last two years,' she told this website. A pneumonectomy results in a mediastinal shift, or the displacement of the central compartment of the chest, called the mediastinum. For Kousoubris, she claims her heart shifted positions and she suffers from atrial fibrillation (AFib), a type of irregular heartbeat where the heart's upper chambers beat chaotically. Even while sitting down, she said her heart rate can spike to 180 beats per minute. She also claims, as detailed by court documents, she spent months during recovery coughing so severely that she often vomited. She has gone back to teaching part time, but the former athlete said she struggles to walk up stairs, let alone run marathons as she previously did. Kousoubris said: 'Breathing is something that we all do. We don't think about it, we just do it. And it's taken me almost two years to be able to walk and move, carry something and breathe at the same time. I had to learn how to do all of that again. 'My new normal is very different now.' As the litigation against MGH continues, Kousoubris hopes speaking out will inspire other patients to do the same. She said: 'As a human being, I feel an obligation. Not everyone's going to be as lucky as me. I'm the lucky one. 'I cannot sit back and be silenced. Maybe it'll save one life or invoke some change.'
